Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Miller

Showing results (11-20 of 313) with videos related to

Pageof 32
Sort By:
Onkologie|February 19, 2010
[First-line therapy of metastatic renal cell carcinoma--update 2009]Kurt Miller
MMW Fortschritte Der Medizin|September 3, 2009
[And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)]Kurt Miller
European Urology|September 17, 2010
Words of wisdom. Re: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Scher HI, Beer TM, Higano CS, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials ConsortiumKurt Miller
Oncology Research and Treatment|April 3, 2017
[Not Available]Kurt Miller
Aktuelle Urologie|March 29, 2019
[Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)]Kurt Miller
Aktuelle Urologie|August 27, 2020
Kurt Miller
Aktuelle Urologie|July 14, 2023
[Management of metastatic hormone-sensitive prostate cancer - Current treatment options, criteria for progression and switch of therapy]Kurt Miller
Der Urologe. Ausg. A|August 13, 2016
[Quality in urology]Kurt Miller
European Urology|December 10, 2009
Words of wisdom. Re: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. Whitman EJ, Groskopf J, Ali A, et al. J Urol 2008;180:1975-8; discussion 1978-9Kurt Miller
BJU International|July 24, 2009
Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancerKarim Fizazi, Kurt Miller
Pageof 32

Showing results (11-20 of 313) with videos related to

Sort By:
Pageof 32
Onkologie|February 19, 2010
[First-line therapy of metastatic renal cell carcinoma--update 2009]Kurt Miller
MMW Fortschritte Der Medizin|September 3, 2009
[And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)]Kurt Miller
European Urology|September 17, 2010
Words of wisdom. Re: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Scher HI, Beer TM, Higano CS, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials ConsortiumKurt Miller
Oncology Research and Treatment|April 3, 2017
[Not Available]Kurt Miller
Aktuelle Urologie|March 29, 2019
[Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)]Kurt Miller
Aktuelle Urologie|August 27, 2020
Kurt Miller
Aktuelle Urologie|July 14, 2023
[Management of metastatic hormone-sensitive prostate cancer - Current treatment options, criteria for progression and switch of therapy]Kurt Miller
Der Urologe. Ausg. A|August 13, 2016
[Quality in urology]Kurt Miller
European Urology|December 10, 2009
Words of wisdom. Re: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. Whitman EJ, Groskopf J, Ali A, et al. J Urol 2008;180:1975-8; discussion 1978-9Kurt Miller
BJU International|July 24, 2009
Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancerKarim Fizazi, Kurt Miller
Pageof 32